iTeos Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of iTeos Therapeutics generated cash of -$103,756,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,113,000 last year. Net change in cash is therefore -$33,587,000.
Cash Flow
| 2018 | -19.09M | -299K | 23.50M |
|---|---|---|---|
| 2019 | -23.14M | -926K | 22.53M |
| 2020 | -25.17M | -377K | 340.33M |
| 2021 | 513.14M | -1.24M | 3.65M |
| 2022 | -111.19M | -446.06M | 1.98M |
| 2023 | -103.75M | 72.65M | 1.11M |
ITOS Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 285.03M | 848.83M | 336.45M | 19.99M | 22.05M | 18.81M |
Operating activities | ||||||
Net income | -112.64M | 96.65M | 214.52M | -38.03M | -22.45M | -18.05M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 898K | 803K | 603K | 535K | 611K | 505K |
Stock-based compensation expense | 27.02M | 21.56M | 13.79M | 4.29M | 809K | 0 |
| Deferred income tax benefit | 27.02M | 21.56M | 13.79M | 4.29M | 809K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 3.98M | -3.34M | 5.03M | -4.85M | 1.08M |
Inventories | 0 | -3.98M | 3.34M | -5.03M | 4.85M | -1.27M |
Accounts payable | 3.03M | 2.76M | 2.28M | 1.67M | -155K | -133K |
Cash generated by operating activities | -103.75M | -111.19M | 513.14M | -25.17M | -23.14M | -19.09M |
Investing activities | ||||||
Purchases Of Investments | -290.54M | -445.00M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.96M | -938K | -1.18M | -356K | -721K | -226K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 72.65M | -446.06M | -1.24M | -377K | -926K | -299K |
Financing activities | ||||||
Common Stock Issued | 1.11M | 925K | 2.94M | 213.66M | 22.47M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -332K | 0 | -226K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.11M | 1.98M | 3.65M | 340.33M | 22.53M | 23.50M |
Net Change In Cash | -33.58M | -563.79M | 512.38M | 316.46M | -2.06M | 3.23M |
Cash at end of period | 251.45M | 285.03M | 848.83M | 336.45M | 19.99M | 22.05M |
| Data source | Data source | Data source | Data source |